Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419419 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
A Phase 3 study of Autoimmune Diseases and Scleroderma, sponsored by MediQuest Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 12
- Study locations
NCT00419419: Completed Phase 3 study of Autoimmune Diseases and Scleroderma, sponsored by MediQuest Therapeutics.
NCT00419419 is a Phase 3 study of Autoimmune Diseases and Scleroderma that has completed, run by MediQuest Therapeutics. The registered enrollment target is 80 participants, below the 975-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (92% lower). The trial reports 12 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00419419, a Phase 3 study of Autoimmune Diseases and Scleroderma, has completed, sponsored by MediQuest Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
Conditions Studied
Interventions
- DRUG Topical AmphiMatrix with nitroglycerin (MQX-503)
Study Locations (12)
Other
- Lund University Hospital - Lund
- Royal National Hospital for Rheumatic Diseases - Bath
- Ninewells Hospital and Medical School - Dundee
- University of Leeds - Leeds
- Royal Free Hospital - London
- Hope Hospital - Salford
California
- Standford Medical School - Stanford
Connecticut
- University of Connecticut - Farmington
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
New York
- The Center for Rheumatology - Albany
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-12 |
| Phase | Phase 3 |
What the finished NCT00419419 record still lists
NCT00419419 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 975-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Autoimmune Diseases appearing as the primary indexed condition, and to 1 intervention - of which Topical AmphiMatrix with nitroglycerin (MQX-503) is the first listed.
NCT00419419 lists 12 locations in 7 states (Other, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT00419419 about?
NCT00419419 is a clinical study titled "Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon". The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
What is the current status of trial NCT00419419?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2006-12.
What conditions does trial NCT00419419 study?
This clinical trial studies the following conditions: Autoimmune Diseases, Scleroderma, Raynaud's Disease.
What interventions are being tested in trial NCT00419419?
The interventions under investigation include: Topical AmphiMatrix with nitroglycerin (MQX-503) (DRUG).
Who is sponsoring clinical trial NCT00419419?
This trial is sponsored by MediQuest Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00419419 being conducted?
This trial has 12 study locations across California, Connecticut, District of Columbia, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autoimmune Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00419419's enrollment target sits among peer trials
80 15th of 25 higher than 11 of 25 other Autoimmune Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autoimmune Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)
COMPLETED · Phase 3
-
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
COMPLETED · Phase 3
-
Rheumatology Diet Study
RECRUITING
-
Collection and Distribution of Biospecimens for Novel Research Uses
RECRUITING
-
Ovarian Tissue Cryopreservation for Fertility Preservation
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia